WHAN IN PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,830 KRW | -0.29% |
|
+1.77% | -8.05% |
| 2023 | Whan In Pharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2015 | Whanin Pharmaceutical Co. Ltd.(KOSE:A016580) added to Russell Global Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Its low valuation, with P/E ratio at 9.2 and 8.46 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- With regards to fundamentals, the enterprise value to sales ratio is at 848.51 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.05% | 153M | - | ||
| +19.62% | 43.34B | B- | ||
| +20.44% | 21.96B | B+ | ||
| +10.86% | 14.09B | - | ||
| +13.07% | 13.64B | B+ | ||
| +37.46% | 11.43B | B | ||
| -8.59% | 6.86B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +8.46% | 5.22B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A016580 Stock
- Ratings Whan In Pharm Co.,Ltd.
